RAPT Therapeutics to Announce Initial Data from Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications

Rhea-AI Summary

RAPT Therapeutics announced plans to present initial data from its Phase 1/2 clinical trial of FLX475 for multiple cancer indications on November 16, 2020. The conference call will occur at 8:30 a.m. ET, and a live webcast will be available on the company's website. RAPT focuses on developing oral small molecule therapies for unmet needs in oncology and inflammatory diseases. Their drug candidates target key immune drivers, including CCR4. This data release is expected to provide insights into the efficacy and potential market impact of FLX475.

Positive

• RAPT plans to present Phase 1/2 trial data for FLX475 on November 16, indicating progress in drug development.
• The focus on multiple cancer indications may expand the potential market for FLX475.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that the Company plans to present initial data from its Phase 1/2 clinical trial of FLX475 in patients with multiple cancer indications in a premarket press release and webcast on Monday, November 16, 2020.

RAPT will host a conference call accompanied by a slide presentation at 8:30 a.m. ET on Monday, November 16^th. The live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. The call can be accessed by dialing (833) 672-0665 (domestic) or (929) 517-0344 (international) and refer to conference ID 6772479. The webcast will be available for replay for two weeks. Please connect to the website 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that are in the discovery stage of development.

RAPT Media Contact:
Angela Bitting
media@rapt.com
(925) 202-6211

RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

FAQ

What is the purpose of RAPT's Phase 1/2 clinical trial for FLX475?

The trial aims to evaluate the efficacy and safety of FLX475 in treating multiple cancer indications.

When will RAPT present the initial data from the FLX475 trial?

RAPT will present the initial data on November 16, 2020, at 8:30 a.m. ET.

How can I access the live webcast of RAPT's presentation?

The live webcast can be accessed on RAPT Therapeutics' website, with an audio archive available for two weeks.

What are the implications of the FLX475 trial results for RAPT's market impact?

Positive trial results could enhance RAPT's market position by demonstrating the effectiveness of FLX475 in treating cancer.